Compare SCM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SCM | LXEO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.2M | 369.8M |
| IPO Year | 2012 | 2023 |
| Metric | SCM | LXEO |
|---|---|---|
| Price | $8.80 | $4.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $9.00 | ★ $18.44 |
| AVG Volume (30 Days) | 170.1K | ★ 731.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 14.22% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $0.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $149.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $3.60 |
| 52 Week High | $15.39 | $10.99 |
| Indicator | SCM | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 35.19 |
| Support Level | $8.43 | N/A |
| Resistance Level | $9.85 | $7.90 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 12.12 | 2.84 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.